EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA).
Year: 2025
Type: article
Study design: Study Protocol
Source: Journal of Clinical Oncology
Authors: Michail Ignatiadis, Emmanouil S. Saloustros, Ana Joaquim, Fanny Grillet, Yiola Marcou, Sonia Pernas, Patrick Neven, Sonia Del Barco Berron, Jose Juan Ponce-Lorenzo, Catharina Willemien Menke-van Der Houven Van Oordt, Catherine Margaret Kelly, Mathias Konrad Fehr, Evangelia Razis, Theodoros Foukakis, Matteo Lambertini, Francois Clement Bidard, Coralie Poncet, Wolfgang Janni
Institutions: Université Libre de Bruxelles, Institut Jules Bordet, University Hospital of Larissa, European Organisation for Research and Treatment of Cancer, European Organisation for Research and Treatment of Cancer, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Universitair Ziekenhuis Leuven, GEICAM – Spanish Breast Cancer Group, Hospital General Universitario de Alicante Doctor Balmis, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Amsterdam University Medical Centers, Cancer Center Amsterdam, St. James's Hospital, Kantonsspital Frauenfeld, Hygeia Hospital, Karolinska Institutet, Ospedale Policlinico San Martino, University of Genoa, Université de Versailles Saint-Quentin-en-Yvelines, Institut Curie, University Hospital Ulm
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410820960